Xencor, Inc.
XNCR Healthcare Biotechnology
Xencor, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $125.6 million, up 13.7% from fiscal 2024. In the quarter to June 2026, revenue grew 17.5%, EPS grew 29.3% and free cash flow fell 52.9%, each against the same quarter a year earlier.
Follow XNCR
Xencor, Inc. (XNCR) EV/Sales
As of 22 October 2026, Xencor, Inc. (XNCR) trades at a EV/Sales of 15.5×. Over the past ten years it has ranged from 1.6× (August 2025) to 102× (July 2015); the current reading is higher than 73% of that period. That is above the Biotechnology industry median of 9.9× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 5.6× | (46.27%) |
| FY2024 | 10.5× | 91.50% |
| FY2023 | 5.5× | (8.32%) |
| FY2022 | 6.0× | (19.41%) |
| FY2021 | 7.4× | (52.19%) |
| FY2020 | 15.5× | 70.72% |
| FY2019 | 9.1× | (54.29%) |
| FY2018 | 19.9× | 74.77% |
| FY2017 | 11.4× | 36.83% |
| FY2016 | 8.3× | (51.27%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 8.4× | 40.91% |
| Mar 2026 | 6.0× | 5.99% |
| Dec 2025 | 5.6× | 52.32% |
| Sep 2025 | 3.7× | 84.93% |
| 39 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ZBIO Zenas BioPharma, Inc. compare | n/m |
| TRVI Trevi Therapeutics, Inc. compare | n/m |
| MLYS Mineralys Therapeutics, Inc. compare | n/m |
| BRVE Braveheart Bio, Inc. compare | n/m |
| NVAX Novavax, Inc. compare | 2.9× |
| SEPN Septerna, Inc. compare | 14.8× |
| XNCR Xencor, Inc. | 15.5× |
| PVLA Palvella Therapeutics, Inc. compare | 37.4× |
| ADRX ADARx Pharmaceuticals, Inc. compare | — |
| Biotechnology industry median | 9.9× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)